Media Center


PAGE:   1 2 3

Sandoz’s Carol Lynch talks about the “Big Break” for biosimilars

May 18, 2015

Read The Medicine Maker’s Biosimilars special edition, including an interview with Carol Lynch, Sandoz Head of Biopharmaceuticals & Oncology Injectables.

The Medicine Maker interviews Sandoz’s Nick Haggar

November 24, 2014

Nick Haggar: “Opening up access to medicine is something Sandoz takes seriously.”

“In Italy, patients receive biosimilars as first-line therapies”

November 11, 2014

Nick Haggar, Sandoz Head of Western Europe, Middle East & Africa and President of the European Generic Medicines Association (EGA), talks to leading Spanish newspaper "La Razón" about how to ensure the success of biosimilars in Spain, Europe and beyond.

Promoting the safety, efficacy and value of generic medicines

November 04, 2014

Nick Haggar, President of the European Generic medicines Association (EGA) and Sandoz Head of Western Europe, Middle East & Africa, talks to Romania’s Health Policy Journal about the growing importance of generic medicines and the EGA’s long-term vision for sustainable global access to affordable, high-quality healthcare.

Efficacy of generics depends on quality

October 14, 2014

Richard Francis, Global Head of Sandoz, talked to leading Russian newspaper Rossiyskaya Gazeta about how to ensure the quality and efficacy of generics.

Leading the Way in Biosimilars and Differentiated Generics

August 06, 2014

France’s leading financial newspaper, Les Echos, has published an interview with Sandoz France Country Head Frédéric Collet, highlighting Sandoz’s global leadership position in biosimilars and differentiated generics.

The growing importance of generic medicines for a sustainable global healthcare system

July 02, 2014

Sandoz’s Nick Haggar, the President of the European Generics Association, explains the key challenges and opportunities facing the generic medicines industry in an interview with Correo Farmaceutico, Spain’s leading trade publication.

Sandoz Highlighted in leading finnish financial newspaper

June 16, 2014

Sandoz WEMEA Head Nick Haggar explains the value of generics in an interview with Kauppalehti, Finland's leading financial newspaper -- one of a three-part series on the subject.

Sandoz business strategy featured in Generics Bulletin

June 12, 2013

Journalist Aidan Fry of Generics Bulletin interviews Jeff George, Sandoz Global Head, and details the Sandoz business strategy in a comprehensive article.

Sandoz Head Jeff George Named Top "40 Under 40"

Holzkirchen, Germany, October 11, 2012

Jeff George, Global Head of Sandoz, has been named part of Fortune Magazine’s 2012 Top "40 Under 40"

Emerging Pharma Leaders 2012

Pharmaceutical Executive, July 10, 2012

Shannon Klinger, VP of Legal and Intellectual Property, and North American General Counsel, Sandoz Inc. was named one of the emerging pharma leaders in 2012. Read about her story at

Investor Perspective: Biosimilars and Sandoz

Basel, Switzerland, June 25, 2012

With the recent US Food and Drug Administration (FDA) hearing held on May 11, 2012 in Washington, DC, biosimilars are back in the news – and with good reason.

BioForum: Biosimilars - Pioneering the Future

March 08, 2012

On 24th May 2012 in Brno, Czech Republic, during BioForum, one of the keynote speakers - Dr. Steffen Wagner, Head Commercial Operations Central & Eastern Europe at Sandoz – will present a talk: “Biosimilars – Pioneering the Future”. Dr. Wagner, formerly Director Global Strategic Planning at Sandoz and Engagement Manager with McKinsey and Company’s Pharmaceutical Industry Practice, will discuss the development process, key challenges, regulatory environment, requirements for successful commercialization and key success factors for companies in the field.

Mark McCamish Presents Sandoz perspective on FDA biosimilar guidelines on BioCentury TV

February 23, 2012

Mark McCamish, Head of Global Biopharmaceutical Development at Sandoz, was invited by BioCentury TV to present the industry perspective on the FDA’s new biosimilar guidance document.

Enoxaparin gives Sandoz injectables lead

Generics Bulletin, p.5, February 03, 2012

Sandoz claims it is now the world’s leading supplier of generic injectables after 2011 sales of its US rival to Sanofi’s Lovenox (enoxaparin) narrowly exceeded annual sales of US$1.0 billion. Retail sales of the firm’s anti-infective injectables rose by a tenth last year, while it also benefitted from the roster of oncology drugs acquired by paying US$1.3 billion for Austria’s Ebewe Pharma in September 2009.

Hexal moves into tenders

Generics Bulletin, p.23, February 03, 2012

When Germany’s AOK group of statutory health insurance funds announced the results of its seventh round of tender contracts in late- November last year, Sandoz grabbed the headlines for more than one reason. Novartis’ generics business led the way by capturing 145 of the 737 regional supply contracts awarded, ahead of Stada in second place on 127 contracts and Teva in third with 118 of the contracts handed out by the fund, which accounts for just over a third of Germany’s statutory health insurance market.

Fortune's 40 under 40: Jeff George ranked number nine.

October 21, 2011

They're the hottest young stars in business across the globe. They're innovators, disrupters, and job creators; in fact, it's a pretty safe bet you're going to be working for them someday -- if you aren't already! They're in technology, yes, but also in movies, music, athletic wear, and even curry-flavored chocolate. And the scary thing is they're just getting started

Sandoz strikes Japanese licensing deal with Nipro

Generics Bulletin, p.01, July 15, 2011

Sandoz will license and co-develop products for the Japanese market with Nipro Corporation as part of a strategic alliance between the two companies. Having worked with Nipro on “various product licensing deals” since 2007, Sandoz said the latest agreement expanded areas of co-operation between the two companies to include cross-licesing existing portfolios and co-developing future products across a number of therapeutic areas. The “first wave” of cross-licensed products would be launched within “the next several months”, Sandoz added.

Sandoz' enoxaparin share nears 50%

Generics Bulletin, p.05, May 06, 2011

Winning new customers for its rival to Sanofi-Aventis’ Lovenox (enoxaparin) lifted Sandoz’ share of the US market for the anticoagulant to almost 50% in the first quarter of this year, according to Jeff George, global head of Novartis’ generics division.

Sandoz aims at asthma by signing deal for Oriel

Generics Bulletin, p.01, April 23, 2011

Sandoz has strengthened its position in the respiratory generics market by signing a definitive agreement to acquire privately-held US company Oriel Therapeutics for an undisclosed fee. The deal for Oriel will give Sandoz “three promising development projects” targeting leading brands for asthma and chronic obstructive pulmonary disease (COPD), as well as the FreePath drug-delivery system and Solis multi-dose dry-powder inhalers.

Worldwide experience with biosimilar development

mAbs 3:2, pp.212-220, March 01, 2011

Mark McCamish, Sandoz's Head of Global Biopharmaceutical Development, co-authored a peer-reviewed article on the importance of biosimilar development.

Enoxaparin makes a difference for Sandoz

Generics Bulletin, p.9, February 01, 2011

AUS$462 million contribution from the generic version of Sanofi-Aventis’ Lovenox (enoxaparin) blockbuster that Sandoz launched last July in the US helped to lift the proportion of Sandoz’ US$8.52 billion turnover last year that the firm derived from ‘differentiated’ products by 10 percentage points to 42%, or around US$3.6 billion.

Lovenox rival brings in US$292mn for Sandoz

Generics Bulletin, p.01, November 01, 2010

Sandoz’ unique generic rival to Sanofi-Aventis’ Lovenox (enoxaparin) blockbuster in the US generated sales of US$292 million in just over two months between its launch on 23 July and 30 September. With a market share climbing to more than 45%, the antithrombotic agent – developed in collaboration with Momenta – exceeded Sandoz’ expectations, according to Sandoz’ head Jeff George.

Focus on differentiation accelerates Sandoz’ rise

Generics Bulletin, pp. 20-21, November 01, 2010

A strategic focus on biosimilars, injectable cancer therapies and respiratory drugs is paying off for Sandoz, the company’s global head Jeff George told Aidan Fry.

Sandoz wins the race for US rival to Lovenox

Generics Bulletin, p.01, August 06, 2010

Sandoz has won the race to become the first company to obtain approval from the US Food and Drug Administration (FDA) for Sanofi-Aventis’ US$2.7 billion anticoagulant brand Lovenox (enoxaparin sodium). Sandoz said it had started shipping the antithrombotic agent – which it developed in collaboration with Momenta Pharmaceuticals – immediately upon receiving FDA approval.

Generic Medicines: Essential contributors to the long-term health of society

April 01, 2010

IMS's Alan Sheppard looks at the sustainability of the generics sector and assesses its benefits to the provision of healthcare across Europe.

Sandoz’ biosimilar sales top US$100mn in 2009

Generics Bulletin, p.01, February 01, 2010

Sandoz’ sales of its three biosimilar brands – Omnitrope (somatropin), Binocrit (epoetin alfa) and Zarzio (filgrastim) – increased by 73% in local currencies last year, reaching combined annual sales of US$118 million.

Sandoz claims US tacrolimus first

Generics Bulletin, p.01, August 12, 2009

Sandoz claims to have become the first company to launch a generic equivalent to Astellas’ Prograf (tacrolimus) immunosuppressant in the US. Quoting IMS Health data for the year ended April 2009, the generics firm said annual US Prograf sales were US$929 million.

Sandoz agrees to spend C925 million on Ebewe

Generics Bulletin, p.01, June 01, 2009

Sandoz has signed a definitive agreement to pay C925 million (US$1.29 billion) in cash for generic injectables specialist Ebewe Pharma. The deal excludes the Austrian firm’s injectable neurological products business, but includes Ebewe’s production plant in Unterach near Salzburg, Austria, and research centres in Austria and the US.

PAGE:   1 2 3